Magunguna mafi tsada na 2019

Kamfanin

Amurkawa sun fi kashewa a kan magungunan likitanci fiye da kowane yawan mutane a duniya. Matsakaicin ɗan ƙasar Amurka yana ciyarwa $ 1,025 a kowace shekara a kan magani - wannan haɓaka-hauhawar farashi sau 11 ya haɓaka tun 1960, a cewar bayanai daga Cibiyar Peterson kan Kiwon Lafiya da Kaiser Family Foundation.

Yana da saboda takaddun magani suna da tsada.

Magunguna 10 da aka fi tallatawa suna da farashin farashi daga $ 488 zuwa $ 16,938 a kowane wata ko kuma hanyar magani, in ji Ma'aikatar Lafiya da Ayyukan Dan Adam . Kuma, bincikenmu ya nuna cewa yawancin magungunan da aka ba da izini akai-akai suna tsada fiye da hakan.

Watau, akwai da yawa sosai magunguna masu tsada a can. Waɗannan su ne magunguna mafi tsada, a cewar bayanan SingleCare. Farashin da aka lissafa a ƙasa suna nuna farashin kuɗi-abin da ake sa ran abokin ciniki ya biya idan ba shi da inshora ko takardar sayan magani.

Drug	Matsakaicin farashin wadatar watannin 1
Afinitor	$ 33,001.08
Humira	$ 7,037.81
Enbrel	$ 4,944.95
Xeljanz	$ 4,694.13
Forteo	$ 3,639.85
Glatiramer Acetate	$ 3,378.50
Norditropin	$ 3,377.89
Ribaddamarwa	$ 3,356.06
Atripla	$ 3,215.15
Biktarvy	$ 3,214.05

1. Afinitor

28-farashin wadata: $ 33,001.08

Afinitor, wani magani na chemotherapy da ake amfani dashi don magance koda, pancreatic, nono, da kuma cutar sankara, shine ɗayan magunguna mafi tsada a wajen-amma waɗanda ke da takardar sayan magani suna buƙatar samun shi don shirin maganin su. Sau da yawa, ana bayyana tsawon lokacin jiyya tare da Afinitor ta hanyar ganewar likita. Marasa lafiya da aka gano tare da Subependymal Giant Cell Astrocytoma sun sami matsakaici na tsawon jiyya na watanni 24.4. Matsakaicin tsaka-tsakin jiyya ga marasa lafiyar da aka gano da Renal Cell Carcinoma kwanaki 141 ne. Wannan shine mafi ƙarancin kuɗin (gulp): $ 166, 184.01 don matsakaita zagaye na jiyya.

A halin yanzu, babu wata hanya ta daban don maganin don taimakawa rage farashin. Wani mai kirkirar kwaya ya rasa shari'ar mallaka a kotuna a farkon 2019, wanda zai iya ba da izinin ƙirƙirar sifa iri ɗaya. Marasa lafiya masu biyan kuɗi suna kallon farashin $ 33,000-da ƙari. Amma akwai hanyoyi don adanawa a kan allunan Afinitor 5 mg. Bisa lafazin Medicare ,Kashi 100 na Medicare Sashe na D da Shirye-shiryen Amfanin Medicare sun rufe wannan maganin.

2. Humira

28-farashin wadata: $ 7,037.81

Humira wani maganin rigakafi ne wanda ake amfani dashi don magance cututtukan zuciya, psoriasis, cutar Crohn, da ulcerative colitis. Ya kasance magungunan da aka fi sayarwa (wanda shine mafi riba) a cikin ƙasar tun daga 2012, kuma ba alamun alamun raguwa. A cikin 2018, umarnin Humira ya haura sama da dala biliyan 14, wanda ya karu fiye da 60% fiye da shekarar da ta gabata-duk da rigima suna na ilimin ilimin halittu.

ZUWA Nazarin 2016 buga ta Jaridar Medicalungiyar Likitocin Amurka hakan bai sami wata hujja ta alaƙa tsakanin bincike da farashin ci gaba da farashi ba; Maimakon haka, ana siyar da magungunan ƙwayoyi a Amurka da farko akan abin da kasuwa zata ɗauka. Amma har yanzu, farashin Humira na ci gaba da hauhawa.Tfarashin Humira ya tashi daga kusan $ 19,000 a shekara (a 2012) zuwa fiye da $ 38,000 a shekara (a 2019), kowane mai haƙuri, bayan ragin-bisa ga bayanan da New York Times , daga kamfanin SSR Health, wani kamfanin bincike. Wannan kari ne na dari bisa dari. Amma far wadanda suka dogara da maganin, akwai labari mai dadi da ke zuwa a 2023: maganin biosimilar da ake kira Hyrimoz. Kada a rikice da kwayoyi masu amfani da kwayoyin, biosimilarsne kama sosai magunguna waɗanda ke kusa isa cikin kwafi don aiwatar da maganin warkewa da sakamakon asibiti (yayin da kwayar cutar ta dace da magungunan asali). FDA ta amince Hyrimoz kuma za'a iya siyar dashi a Amurka ranar 30 ga Satumba, 2023.

3. Enbrel

28-farashin wadata: $ 4,944.95

Enbrel magani ne na biopharmaceutical wanda ake amfani dashi don magance cututtukan zuciya na rheumatoid, cututtukan zuciya na psoriatic, da sauran yanayi na autoimmune. Kamar dai Humira, Enbrel yana ganin hauhawar tallace-tallace da takaddun cika, duk da lalataccen walat.Enbrel - wanda ya sauka a kasuwar Amurka a 1998 - ya yi rijistar dala biliyan 4.8 a cikin siyarwar Amurka a cikin 2018, a cewar kamfanin Amgen , Inc.

A halin yanzu, masu kera magunguna suna yin farashin shekara guda na maganin Enbrel na 50-mg kashi sama da $ 67,000.Kuma babu nau'ikan halittu a sararin samaniya don taimakawa sauƙaƙa farashin marasa lafiya.Masana biosimilars biyu na Enbrel sun sami izini daga FDA kuma ba a ƙaddamar da su ba har yanzu — gami da ɗaya daga kamfanin masu hada magunguna na SwitzerlandNovartis AGcewa hukumar lafiya ta amince da ita a shekarar 2016,bisa lafazin Jaridar Wall Street Journal mai rahoton lafiya Jared S. Hopkins . Fiye da haƙƙin mallaka 40 sun kare Enbrel, kuma masana'anta, Amgen Inc., sun ci nasara a hukuncin kotu a watan Agusta dangane da haƙƙin mallaka na Enbrel.

4. Xeljanz

30-farashin wadata: $ 4,694.13

Xeljanz sanannen magani ne wanda aka tsara don magance cututtukan zuciya na rheumatoid, cututtukan zuciya na psoriatic, da ulcerative colitis. Amma kwanan nan, magungunan sun ba da labari saboda sabon FDA gargadi mai lakabi cewamai maganin JAK na 10-MG sau biyu a kowace rana, wanda aka kirkira domin saukaka radadin hadin gwiwa da kumburi,ƙaruwahaɗarin daskarewa na jini - kuma mai yuwuwa, mutuwa.

Tya hade da yardar magani don magance ulcerative colitis - yanzu an yarda da shi ne kawai ga marasa lafiyar da ba su amsa ko ba su dace da sauran magunguna ba.Amma duk da irin gargadin da ke tattare da maganin na 10-mg, har ila yau ana ɗaukar 5-mg lafiya, kuma bi da bi ya ga karuwar tallace-tallace da amfani.

5. Forteo

28-farashin wadata: $ 3,639.85

Forteo magani ne na allura wanda ke taimakawa ƙarfafa kasusuwa ga mutanen da ke fama da cutar sanyin ƙashi wanda ke cikin haɗarin karyewa-musamman waɗanda ke fama da cutar daga shan ƙwayoyin cuta kamar prednisone. Yana da nau'ikan roba na homon da aka samo shi a jiki wanda ke inganta haɓakar sabon ƙashi da haɓaka ƙashi. Ana yawan yin allura a cikin cinya ko ciki. An yarda dashi har zuwa watanni 24 na amfani.

A halin yanzu babu wadataccen samfurin. Amma, Pfenix ya sami izinin patent don makamancin haka samfurin , wanda zai iya sa farashin ya sauka idan ya faɗi kan masana'antu. Akwai magungunan da suka kamace su guda biyu a cikin Turai, amma an toshe su a cikin Amurka. Idan kuna buƙatar Forteo, akwai rangwamen mai ƙera kaya akwai don marasa lafiya masu cancanta.

6. Glatiramer Acetate Allura

30-farashin wadata: $ 3,378.50

Allurar Glatiramer acetate ita ce sifar iri ta Copaxone , magani mai allura da ake amfani dashi don magance cututtukan sclerosis da yawa da hana sake komowar MS. Ko da a matsayin jigilar kaya, farashin ya yi yawa - ba ƙasa da takwaran sunan alama ba.

A cikin shekaru 20 da suka gabata, an sami ci gaba sosai game da maganin MS, amma ƙaruwar zaɓuɓɓukan maganin da ake samu bai haifar da hauhawar farashi mai daidaita ba. Sun kasance suna ta karuwa. Daga 2013 zuwa 2018, matsakaiciyar tsadar tsaka-tsakin tsaka-tsakin cututtukan da ake canzawa ta hanyoyin kwantar da hankali kamar glatiramer acetate ya tashi daga $ 60,000 zuwa $ 80,000 bisa ga Multiungiyar Scasa ta leasa ta .asa . Idan kuna fuskantar matsala wajen bada magungunanku, Mylan yayi tanadi don wasu mutane.

7. Norditropin Allura

30-farashin wadata: $ 3,377.89

Norditropin shine haɓakar haɓakar haɓakar roba wanda ke kwaikwayon homonu a cikin gland na pituitary wanda ke motsa girma a cikin jiki: tsayi, gabobi, ƙasusuwa, da tsokoki. Idan aka yi amfani da shi ga yara waɗanda ba sa yin isasshen haɓakar girma, zai iya taimaka musu su zama masu tsayi. Ga manya, yana iya motsa haɓakar tsoka. Lokacin amfani da marasa lafiya ba tare da rashi ba, ba shi da tasiri.

An yi la'akari da magani na musamman, kamar waɗanda aka yi amfani da su don magance yanayi irin su ciwon daji, HIV, ko cututtukan zuciya na rheumatoid. Wadannan nau'ikan magunguna yawanci sun fi tsada, kuma norditropin ba banda bane. Novo Nordisk yana da haƙuri taimako shirin a cikin wuri don taimakawa kewaya fa'idodin inshora da wadatar magunguna.

8. Kaɗa

30-ranar bayarwa farashin: $ 3,356.06

Stribild shine hadaddiyar giyar da aka yi amfani da ita a cikin kwamfutar hannu guda daya da ake amfani da ita don magance kwayar cutar ta HIV da rage kasadar yada cutar ga wasu. Ya ƙunshi magungunan rigakafi guda uku da magani wanda ke taimaka wa sauran suyi aiki sosai. Ko da yake mai tsada, akwai wasu shaidu cewa sau ɗaya a rana haɗakar magungunan kanjamau ba su da tsada mai tsada fiye da wasu zaɓuɓɓuka saboda suna inganta bin magani ga marasa lafiya, wanda zai iya rage haɗarin rikice-rikice ko tsadar asibiti. Wanda ya ƙera kamfanin Stribild, Gileyad , Yana ba da shirye-shiryen taimako na haƙuri idan kuna fuskantar matsala wajen bayar da maganin.

9. Atripla

30-farashin wadata: $ 3,215.15

Atripla wani magani ne na hadin gwiwa wanda ake amfani dashi don magance cutar kanjamau, da rage kasadar yada cutar ga wasu. Ya ƙunshi magunguna uku. A halin yanzu babu nau'ikan sifofin wannan magani, wanda ke sa farashin yayi tsada. Amma, farawa a ƙarshen Satumba 2020, Magungunan Teva An yarda da ƙaddamar da sifa iri ɗaya, wanda zai iya taimakawa inganta kuɗin. Wanda ya kera Atripla, Gileyad , Yana ba da shirye-shiryen taimako na haƙuri idan kuna fuskantar matsala wajen bayar da maganin.

10. Biktarvy

30-farashin wadata: $ 3,214.05

Biktarvy kwaya ce ta hada magunguna guda uku da ake amfani da ita don magance cutar kanjamau. Babu wadatar sifa iri ɗaya. Sabo bayanai ya nuna yana da matukar tasiri a cikin sababbin marasa lafiya, kuma marasa lafiya suna sauyawa daga wasu magunguna, wanda hakan ya haifar kusan-quadrupling sayar da wannan magani a cikin shekara guda duk da kuɗin. Kamar sauran magunguna masu haɗuwa da kwayar cutar HIV, akwai wasu shaidun da ke ragewa farashin magani na dogon lokaci saboda ingantaccen riko. Wanda ya kera kamfanin Biktarvy, Gileyad , Yana ba da shirye-shiryen taimako na haƙuri idan kuna fuskantar matsala wajen bayar da maganin.

To me ke kawo hauhawar farashin?

Ta yaya (kuma me yasa) yawan kuɗin da ake buƙata don magunguna masu yawa suke da yawa haka? Yana da rikitarwa-kuma ya sami tasiri ta wasu dalilai.

Brand-sunan magunguna

Kasuwa mai suna shine inda aka fara kirkirar magunguna, kuma haɓaka sabon magani abu ne mai tsada da ɓata lokaci. Alamu suna da ikon mallakar doka da kariya a tsarin kasuwancin su na farko, wanda hakan ke baiwa masana’antu damar cin gajiyar bukatar maganin su na zamani, da kuma sakawa masu saka hannun jari saboda haqurin su da tsadar bincike da ci gaba, in ji Dana Goldman, shugaban darekta a Cibiyar USC Schaeffer ga Manufofin Kiwon Lafiya da Tattalin Arziki da kuma Farfesa na Manufofin Jama'a, Magunguna, da Tattalin Arziki. A takaice dai, farashin sabbin magunguna suna da tsada saboda tsadar kawo su kasuwa.

Magunguna na asali

A cikin kasuwar jigilar kaya, labarin ne daban. Lokacin da izinin mallaka akan sabon magani ya ƙare, masana'antun na iya ƙirƙirar sifa iri ɗaya kuma su siyar da shi akan farashi mai rahusa sosai saboda mai haɓaka asalin ya sake biyan kuɗi. Duk da haka, lokaci-lokaci, dabi'un halittu suna da tsada kamar takwarorinsu masu alama, kamar farashi mai tsada don maganin cutar malariya Daraprim , wanda ya ba da labarin a cikin 2015.

Martin Shkreli da Turing Pharmaceuticals sun ɗauki $ 13.50 a kowace kwaya Daraprim (wanda aka samo shi tun shekara ta 1950s) kuma ya ƙara farashin zuwa $ 750 a kowace kwaya. Shrkeli na iya yin wannan saboda farashin Daraprim ya faɗi ƙasa ƙwarai da gaske cewa duk masu samarwa sun fita. Daga nan sai Turing ya shiga ciki kuma ya ba da ikon mallakarsa a kan wani magani wanda ba shi da kariya ta haƙƙin mallaka.

Wannan ya tabbatar da yadda, abin ban mamaki, da magani na asali Kasuwa wani lokaci yana aiki da kyau sosai: Magunguna suna da arha cikin sauri kuma wadatar wadatuwa tana cikin haɗari.

Ta yaya SingleCare zai iya taimakawa

Saboda tsadar magani, yawancin mutane suna dogara ga kamfanonin kiwon lafiya kamar SingleCare don taimaka musu su adana ɗaruruwan (da dubunnan) dala a kan maganin su. A SingleCare, mun yi imanin yana da mahimmanci a samar da rangwamen magani ga kowa a Amurka wanda ke da 'yancin isa, ba tare da la'akari da matsayin inshora ba, in ji Manav Malhotra, VP na bayanai a SingleCare. Kuma yayin da muke ƙoƙarin sa ƙwayoyi su kasance masu araha da sauƙi, babban ɓangare na wannan yana tabbatar da cewa akwai farashi mai sauki ga mabukaci.

Kuma yayin da Amurkawa suka saba cin kasuwa don farashi, ba sa yi da magunguna. Yana da wuya a yi tunanin siyan kowane kaya ba tare da wani tunanin abin da zai ci maka ba har sai ka isa ga rajista, amma wannan a al'adance yadda masana'antar kantin ta yi aiki, in ji Malhotra. Muna son masu sayen su san ainihin abin da za su biya a kowane ɗayan abokan harhada magungunan mu kafin su sa ƙafa ciki. Yawancin masu amfani ba su ma san cewa farashin ya bambanta tsakanin kantin magani kawai a ƙetaren titi daga juna. Kasuwa da mai masarufi mai ƙwarewa ke yanke shawara shine matakin farko zuwa rage farashin.

SingleCare tana ba da jadawalin farashi na gaskiya wanda zai baka damar kwatanta farashin kuɗi da ajiyar SingleCare don ƙwayoyi a cikin shekarar da ta gabata.Bayar da mafi kyawun tanadi yana cikin zuciyar duk abin da SingleCare ke yi. Har ila yau, muna duban magungunan da masu amfani da gaske suke kulawa don ƙayyade inda za mu mai da hankali kan ƙoƙarinmu na rage farashin, Malhotra ya ce. Yana motsa yadda muke yanke shawarar farashinmu da tattaunawarmu tare da abokan harhada kantinmu.

Fara neman maganin ku nan ganin nawa zaka iya ajiya.